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Phyto-oestrogens are plant compounds structurally similar to oestradiol, which have been proposed to have protective effects against
breast cancer. The main class of phyto-oestrogens in the Western diet is lignans. Literature reports on the effect of lignans in breast
cancer risk have been conflicting. We performed three separate meta-analyses to examine the relationships between (i) plant lignan
intake, (ii) enterolignan exposure and (iii) blood enterolactone levels and breast cancer risk. Medline, BIOSIS and EMBASE databases
were searched for publications up to 30 September 2008, and 23 studies were included in the random effects meta-analyses. Overall,
there was little association between high plant lignan intake and breast cancer risk (11 studies, combined odds ratio (OR): 0.93, 95%
confidence interval (95% CI): 0.83–1.03, P¼0.15), but this association was subjected to marked heterogeneity (I
2¼44%). Restricting
the analysis to post-menopausal women, high levels of plant lignan intake were associated with reduced breast cancer risk (7 studies,
combined OR: 0.85, 95% CI: 0.78, 0.93, Po0.001) and heterogeneity was markedly reduced (I
2¼0%). High enterolignan exposure
was also associated with breast cancer (5 studies, combined OR: 0.73, 95% CI: 0.57, 0.92, P¼0.009) but, again, there was marked
heterogeneity (I
2¼63%). No association was found with blood enterolactone levels (combined OR: 0.82, 95% CI: 0.59–1.14,
P¼0.24). In conclusion, plant lignans may be associated with a small reduction in post-menopausal breast cancer risk, but further
studies are required to confirm these results.
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High levels of endogenous circulating oestrogens (Hankinson and
Eliassen, 2007) and use of exogenous oestrogens (Beral, 2003) have
both been associated with increased breast cancer risk. Isoflavones
and lignans are plant compounds structurally similar to
17b-oestrodiol known as phyto-oestrogens, capable of oestrogen
receptor binding (Kuiper et al, 1998; Mueller et al, 2004).
Isoflavones are mostly found in soybean products, which are a
staple of the Asian diet, whereas lignans are the principal group of
phyto-oestrogens in Western diets. Lignans are more widespread
in foods than isoflavones and are present in grain cereals,
vegetables, seeds, tea and coffee (Mazur, 1998a; Mazur et al,
1998b). Microflora in the colon (Setchell et al, 1981) convert plant
lignans into enterolignans, which are detectable in blood and
urine. Their levels have been correlated with the amount of plant
lignans ingested (Nesbitt et al, 1999).
In a recent meta-analysis, an inverse dose-response relationship
was shown between breast cancer risk and soy-food intake in
Asian, but not in Western women (Wu et al, 2008). Lignans have
been shown to exhibit anti-carcinogenic properties (Wang et al,
1994; Prasad 2000; Bergman Jungestro ¨m et al, 2007), and it is
hypothesised that exposure to high levels may be associated with a
reduction in breast cancer risk. However, results from a number of
studies in Western populations have been variable. The aim of our
systematic review was to establish whether an association exists
between lignan exposure and breast cancer risk, and to quantify
the association through meta-analyses to inform evidence-based
dietary guidelines.
MATERIALS AND METHODS
A systematic search of Ovid Medline (US National Library of
Medicine, Bethesda, MD, USA), BIOSIS (Thompson Reuters, NY,
USA) and EMBASE (Reed Elsevier PLC, Amsterdam, The Netherlands)
databases for relevant studies published up to and including the
date, 30 September 2008 was carried out. Relevant studies included
at least one keyword or Medical Subject Heading from each of the
following; (i) plant lignans (matairesinol, secoisolarisiresinol,
pinoresinol and lariciresinol), (ii) enterolignans (enterolactone
and enterodiol) and (iii) breast cancer. The search strategy
excluded reviews, animal and cell culture studies but did not
impose any language restrictions.
Abstracts and full texts, where required, were independently
screened by two investigators to establish the suitability for
inclusion. Studies had to be of case–control or cohort design,
evaluating the risk of invasive breast cancer in relation to lignan
exposure and reporting odds ratios (ORs) or relative risks, as well
as 95% confidence intervals (95% CIs). Cited references were also
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database searches.
Eligible publications were then assessed independently by three
reviewers. A structured form was used to extract information
about the study, subjects’ characteristics including menopausal
status, confounding factors and results. Wherever multiple
publications of the same study were available, the paper with the
most complete set of data was chosen.
Studies were then categorised as those: (i) assessing total plant
lignan intake or intake of individual plant lignans if the total was
not measured; (ii) investigating exposure to enterolignans
(enterolactone and enterodiol) by using values produced from
food by in vitro fermentation models; and (iii) examining
enterolactone levels in the blood (either plasma or serum). The
blood levels of enterodiol were measured in a small number of
studies (Piller et al, 2006b; Verheus et al, 2007; Ward et al, 2008)
and were, therefore, not considered for analysis.
Separate meta-analyses were performed for each group of
studies described in the Methods section using adjusted ORs or
relative risks for the highest vs the lowest categories of exposure. If
different levels of adjustment had been carried out, the results
from the most fully adjusted model were used.
Random effects models were used to calculate pooled estimates,
as we anticipated heterogeneity between observational studies
(DerSimonian and Laird, 1986). Study-specific weights in the
random effects model were calculated and scaled to percentages.
The I
2-statistic was used to test for heterogeneity (Higgins et al,
2003). Publication or selection bias was investigated by checking
for asymmetry in funnel plots (Egger et al, 1997).
Analysis was repeated and sub-divided by menopausal status
(pre- and post-menopausal). Statistical analyses were performed
using the STATA version 9.2 software (Stata Corporation 2005,
College Station, TX, USA).
RESULTS
Following screening of abstracts and full texts and grouping into
categories, 27 of the 33 articles identified were selected for data
extraction. Multiple publications were identified for a number of
studies. Four articles (Grace et al, 2004; McCann et al, 2006;
Thanos et al, 2006; Piller et al, 2006b) were excluded, as they were
based on smaller subgroup analysis of their respective larger
studies. The format of certain results prevented their use, but were
provided by the authors in a suitable form and therefore included
in this study. Overall, 23 publications were used, providing data for
6 cohort, 6 nested case–control and 10 case–control studies. Each
article contributed data to one or more meta-analyses resulting in
12 articles on plant lignan intake (see Table 1), 5 on enterolignan
exposure (see Table 2) and 9 on blood enterolactone levels
Table 1 Characteristics of studies included in the review of plant lignans and breast cancer risk
First author/
(year)/ country Parent study
Study design
(follow-up) Cases
Controls/
cohort
size
Menopausal
status
Lignans
measured
Dietary
assessment
Adjusted
confounders
Horn-Ross et al
(2002) United States
California Teachers
Study
Prospective
cohort (222249
person-years; 2
years**)
711 111526 Pre-M and
Post-M
M, S Self-reported
113-item FFQ
Age at 1st birth and menarche, BMI, daily
caloric intake, ethnicity, family history,
menopausal status, nulliparity, physical
activity
Touillaud et al (2006)
France
E3N Study Prospective
cohort (117652
person-years; 4.2
years*)
402 26868 Pre-M M, S, P, L Self-reported
208-item FFQ
Age at 1st birth and at menarche,
alcohol, BBD, BMI, education, family
history, energy, geographic area, height,
OC, parity
Touillaud et al (2007)
France
E3N Study Prospective
cohort (383425
person-years; 7.7
years*)
1469 58049 Post-M M, S, P, L Self-reported
208-item FFQ
Age at 1st birth, at menarche
menopause, alcohol, BBD, BMI, energy,
family history, height, HRT, OC, parity,
smoking
Hedelin et al (2008)
Sweden
SWLH cohort Prospective
cohort (13 years)
1014 1014 Pre-M and
Post-M
M, S, P, L, Sy,
Med
Self-reported 80-item
FFQ
Age at menarche and 1st pregnancy,
alcohol, BMI, energy, family history, OC,
parity, saturated fat
Suzuki et al (2008)
Sweden
SMC Study Prospective
cohort (430339
person-years;
8.3 years**)
1284 51823 Post-M M, S, P, L Self-reported 67-item
FFQ (1987), 93-item
FFQ (1997)
Age at 1st birth, menarche and
menopause, alcohol, BBD, BMI,
education, energy, family history, height,
HRT, OC, parity
Horn-Ross et al
(2001) United States
Bay Area Breast
Cancer Study
Population-based
case–control
1272 1610 Pre-M and
Post-M
M, S Self-reported 94-item
FFQ
Age, age at menarche, BBD, BMI, daily
caloric intake, education, family history,
HRT, lactation, menopausal status, parity,
race
dos Santos Silva et al
(2004) United
Kingdom
Case–control
(GP’s patient lists)
240 477 Pre-M and
Post-M
M, S Interviewed 207-item
FFQ
Age at 1st birth and at menarche,
education, family history, lactation,
menopausal status, parity
Linseisen et al (2004)
Germany
Population-based
case–control
278 666 Pre-M M, S Self-reported
176-item FFQ
Alcohol, BMI, education, energy, family
history, lactation, parity
McCann et al (2004)
United States
WEB Study Population-based
case–control
1122 2036 Pre-M and
Post-M
M, S Self-reported
98-item FFQ
Age, age 1st birth, at menarche and
menopause, BBD, BMI, education,
energy, age at menopause, parity, race,
smoking
Fink et al (2007)
United States
LIBCSP Study Population-based
case–control
1434 1404 Pre-M and
Post-M
M, S Self-reported 94-item
FFQ
Age and energy
Cotterchio et al
(2008) Canada
Ontario Women’s
Diet and Health Study
Population-based
case–control
3063 3370 Pre-M and
Post-M
M, S, P, L Self-reported
178-item FFQ
Age, age at 1st live birth, BBD, dietary
fibre intake, family history, HRT
Torres-Sanchez et al
(2008) Mexico
Hospital based
case–control
141 141 Pre-M and
Post-M
M, S, P, L Interviewed 100-item
FFQ
Age, energy, lifetime lactation,
menopause status
BBD¼benign breast disease; BMI¼body mass index; E3N¼French Component of the European Prospective Investigation into Diet and Cancer (EPIC) Study; FFQ¼food
frequency questionnaire; GP¼general practitioner; HRT¼hormone replacement therapy; L¼lariciresinol; LIBCSP¼Long Island Breast Cancer Study Project; M¼matairesinol;
Med¼medioresinol; OC¼oral contraceptive; P¼pinoresinol; Peri-M¼peri-menopausal; Pre-M¼pre-menopausal; Post-M¼post-menopausal; S¼secoisolariciresinol;
SMC¼Swedish Mammography Cohort; SWLH¼Scandinavian Women’s Lifestyle and Health Cohort; Sy¼syringaresinol; WEB¼Western New York Exposure and Breast
Cancer Study. *Median follow-up; **Mean follow-up.
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(the most fully adjusted model was used in the meta-analysis) are
shown in Tables 1–3.
There was no association between plant lignan intake and risk
when 11 studies were combined, although there was a slight
protective effect. The risk in the highest intake group was 0.93
times (95% CI: 0.83–1.03, P¼0.15) that of the lowest intake group
(see Figure 1). When studies were analysed by menopausal status,
a statistically significant reduction in risk was seen with the highest
intake category of plant lignans vs the lowest intake in post-
menopausal women (7 studies, combined OR: 0.85, 95% CI: 0.78,
0.93, Po0.001), with little sign of between-study heterogeneity
Table 2 Characteristics of studies included in the review of mammalian enterolignans (enterolactone and enterodiol) and breast cancer risk
First author/
(year)/ country Parent study
Study design
(median
follow-up) Cases
Controls/
cohort size Menopausal status
Diet
assessment Adjusted confounders
Keinan-Boker et al
(2004) The
Netherlands
Prospect- EPIC Prospective Cohort
(5.2 years)
280 80215 Pre-M, Peri-M and
Post-M combined
Self-reported
178-item FFQ
Age at 1st birth and study entry, education,
energy, height, HRT, marital status, OC, parity,
physical activity, weight
Touillaud et al (2006)
France
E3N Study Prospective Cohort
(4.2 years)
402 117652 Pre-M Self-reported
208-item FFQ
Age at 1st birth and menarche, alcohol, BBD, BMI,
education, energy, family history, geographic area,
height, OC, parity
Touillaud et al (2007)
France
E3N Study Prospective cohort
(7.7 years)
1469 383425 Post-M Self-reported
208-item FFQ
Age at 1st birth, at menarche and menopause,
alcohol, BBD, BMI, energy, family history,
geographic area, height, HRT, OC, parity, smoking
McCann et al (2002)
United States
WEB Study Population-based
case–control
301439 316494 Pre-M
Post-M
FFQ Age at menarche, BBD, BMI, education, energy,
family history, parity; further adjusted for age at
menopause
Linseisen et al (2004)
Germany
Population-based
case–control
278 666 Pre-M Self-reported
176-item FFQ
Alcohol, BMI, breast-feeding, education, energy,
family history, parity; controls matched by exact
age to cases
BBD¼benign breast disease; BMI¼body mass index; E3N¼French Component of the European Prospective Investigation into Diet and Cancer (EPIC) Study; FFQ¼food
frequency questionnaire; HRT¼hormone replacement therapy; OC¼oral contraceptive use; Peri-M¼Peri-menopausal; Pre-M¼pre-menopausal; Post-M¼post-menopausal;
Prospect-EPIC¼Dutch Cohort of EPIC Study; WEB¼Western New York Exposure and Breast Cancer Study.
Table 3 Characteristics of studies included in the review of enterolactone exposure as measured in blood and breast cancer risk
First author/
(year)/ country Parent study
Design
(follow-up) Cases
Controls/
cohort size Method
Menopausal
status
Mean ENL cases
(nmol/l)
Mean ENL
controls/cohort
(nmol/l) Adjusted confounders
Boccardo et al (2003)
Italy
Prospective
cohort (6.5 years
after cyst
aspiration)
18 383 TR-FIA Pre-M and
Post-M
14.7 19.6 Age, cyst type and family
history
Hulte ´n et al (2002)
Sweden
VIP, MONIKA
and MSP studies
Nested case–
referent
248 492 TR-FIA Pre-M and
Post-M
26.8 VIP and
MONIKA 19.3 MSP
22.9 VIP and
MONIKA 20.4 MSP
BMI, menopausal status,
smoking
Kilkkinen et al (2004)
Finland
Cross-sectional
population
surveys
Nested case–
control
206 215 TR-FIA Pre-M and
Post-M
25.2 24.0 None
Olsen et al (2004)
Denmark
Diet, Cancer and
Health Study
Nested case–
control
381 381 TR-FIA Post-M Not provided Not provided Age, HRT (through
matching of controls)
Zeleniuch-Jacquotte
et al (2004) United
States
NYU Women’s
Health Study
Nested case–
control
417 417 TR-FIA Pre-M
Post-M
18.3
18.6
15.1
18.9
Age at 1st live birth and
menarche, ln(BMI), family
history, ln(height),
nulliparity
Verheus et al (2007)
The Netherlands
Prospect-EPIC Nested case–
control
383 383 LC/MS Pre-M/Peri-M
Post-M
2.98 (ng/ml)
2.71 (ng/ml)
2.66(ng/ml)
2.65 (ng/ml)
Age at menarche and
family history (Pre-M)
Crude OR (Post-M).
Ward et al (2008)
United Kingdom
EPIC-Norfolk Nested case–
control (9.5 years;
11261 person-
years)
219 891 LC/MS All 5.83 (ng/ml)* 5.00 (ng/ml)* Age, age at menarche,
breast-feeding, energy,
family history, fat, HRT,
OC, menopausal status,
parity, social class, weight
Pietinen et al (2001)
Finland
Kuopio Breast
Cancer Study
Population-based
case–control
194 208 TR-FIA Pre-M
Post-M
16.6
21.2
20.7
28.9
Age at 1st birth and at
menarche, alcohol, area,
BBD, BMI, education, family
history, HRT, OC, physical
activity, smoking, waist to
hip ratio
Piller et al (2006a)
Germany
Population-based
case–control
192 231 TR-FIA Pre-M 11.6 12.2 Age at menarche, alcohol,
BMI, breast-feeding, day of
analysis, education, family
history, OC, parity, time
difference between surgery
and blood sampling day
BBD¼benign breast disease; BMI¼body mass index; ENL¼enterolactone; HRT¼hormony replacement therapy; LC¼liquid chromatography; MONIKA¼Monitoring of
Trends and Cardiovascular Disease Study; MS¼mass spectrometry; MSP¼Mammary Screening Project; NYU¼New York University; OC¼oral contraceptive; Peri-M¼peri-
menopausal; Pre-M¼pre-menopausal; Post-M¼post-menopausal; Prospect-EPIC¼Dutch Cohort of the European Prospective Investigation into Diet and Cancer (EPIC)
Study; TR-FIA¼time-resolved fluoroimmunoassay; VIP¼Va ¨sterbotten Intervention Project. *Median values. Mean values not provided.
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2¼0%, 95% CI: 0, 71, P¼0.46) (see Figure 2). The same effect
was not observed in pre-menopausal women (7 studies, combined
OR: 0.97, 95% CI: 0.82, 1.15, P¼0.73). The funnel plot of studies
examining plant lignan intake and overall breast cancer risk
showed symmetry, suggesting a lack of publication bias.
There was a statistically significant inverse association between
enterolignan exposure and overall risk (combined OR: 0.73, 95%
CI: 0.57, 0.92, P¼0.009) (Figure 3), although there was marked
heterogeneity (I
2¼63%, 95% CI: 0.0, 88, P¼0.04), but there was
no association between exposure and risk by menopausal status
(pre-menopausal breast cancer risk: 3 studies, combined OR: 0.67,
95% CI: 0.44–1.02, P¼0.06; post-menopausal: 2 studies, combined
OR: 0.85, 95% CI: 0.72–1.01, P¼0.06).
There was no association between blood enterolactone and
breast cancer risk (combined OR: 0.82, 95% CI: 0.59–1.14,
P¼0.24) (Figure 4). Results of analysis by menopausal status
were similar for both pre-menopausal women (5 studies, combined
OR: 0.85, 95% CI: 0.45–1.59, P¼0.61) and post-menopausal
women (6 studies, combined OR: 0.86, 95% CI: 0.66, 1.14,
P¼0.28).
DISCUSSION
This is the first systematic review and meta-analysis of exposure to
lignans and breast cancer risk based on studies using dietary
assessments and serum measurements. Although exposure can be
assessed by urine analysis, few studies have used this methodology
and therefore, these were not included (Ingram et al, 1997; den
Tonkelaar et al, 2001; Dai et al, 2002). The results show that there
was no association between plant lignan intake and overall risk,
and this association was subjected to marked heterogeneity.
Fink (2007)
McCann (2004)
Linseisen (2004)
Dos Santos Silva (2004)
Horn-Ross (2001) 1.30 (1.00–1.60)
0.75 (0.44–1.29)
1.10 (0.72–1.70)
0.81 (0.58–1.13)
Cotterchio (2008) 0.81 (0.65–0.99)
Study Combined OR           Plant lignan levels (µg day–1)
0.33 0.5 1 2 3
Combined
Torres-Sanchez (2008)
Horn-Ross (2002) 1.10 (0.80–1.40)
0.82 (0.64–1.04)
Touillaud (2006 2007) 0.88 (0.77–1.01)
Suzuki (2008)
Hedelin (2008) 1.09 (0.91–1.31)
0.83 (0.70–0.97)
0.63 (0.29–1.39)
0.93 (0.83-1.03)α
 , test for heterogeneity  Q=17.9, df=10, P=0.056; I2=44% (95% CI; 0–72%)
 , levels for matairesinol only
NP, not provided
Cohort studies
Case–control studies
Lowest category Highest category
< 65  > 148
< 843   5701 
NP NP
< 712   1036  
< 104   224 
< 85  236
< 298.4 > 1428.2
< 2300  9900
< 329 > 713
< 255 < 653620
< 0.4  > 3.4 
(95% CI)
Figure 1 Forest plot of highest vs lowest plant lignan intake and breast cancer risk.
 , test for heterogeneity Q= 5.7, df=6, P=0.45; I2=0% (95% CI; 0–71%)
NP, values not provided
 , levels for matairesinol only
0.33 0.5 1 2 3
Combined
Combined OR            Plant lignan levels ( g day–1)
(95% CI)            Lowest category   Highest category
Touillaud (2007) 0.83 (0.71–0.96)
Suzuki (2008)
Hedelin (2008) 1.07 (0.83–1.38)
0.83 (0.70–0.97)
Torres-Sanchez (2008)
Cotterchio (2008)
Fink (2007)
McCann (2004)
0.93 (0.71–1.22)
0.69 (0.51–0.94)
0.82 (0.63–1.07)
0.95 (0.43–2.11)
0.85 (0.78–0.93) 
Study
Cohort Studies
Case–control studies
< 878 5701
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< 0.4  > 3.4 
Figure 2 Forest plot of highest vs lowest plant lignan intake and breast cancer risk in post-menopausal women.
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significant reduction in risk and a reduction in heterogeneity.
A significantly decreased risk with increasing enterolignan exposure
was also found. However, there was significant heterogeneity
between studies making it difficult to draw clear conclusions, and
the effect did not persist when analyses were stratified by
menopausal status, although the number of studies included in
these stratified analyses was very small. Finally, there was no
association between enterolactone concentrations in blood and
overall risk, or when analysis was stratified by menopausal status.
The protective action of plant lignans against breast cancer in
post-menopausal, but not in pre-menopausal women, would
suggest that lignan activity has a physiologic effect only at low
oestradiol levels. One of the mechanisms of action may be greater
sex hormone-binding globulin production and binding of free
oestradiol (Adlercreutz et al, 1989, 1992; Zeleniuch-Jacquotte et al,
2004; Low et al, 2007). Binding of type II nuclear oestrogen
receptor (Adlercreutz et al, 1992; Adlercreutz, 2007) and altering
oestrogen synthesis within the breast cells and extragonadal sites,
such as the adipose tissue, are other possible mechanisms
(Adlercreutz et al, 1993; Saarinen et al, 2007). Enterolactone has
been shown to decrease local oestrogen production by inhibiting
17-hydroxysteroid dehydrogenase type I and aromatase (Wang
et al, 1994; Brooks and Thompson, 2005).
The apparent protective effect of dietary plant lignans in post-
menopausal women is not supported by the findings from the
meta-analysis of studies that measured the enterolactone levels in
their blood. It would be expected that women consuming larger
amounts of plant lignans would have a higher circulating
concentration of enterolactone. There are a number of possible
reasons for this disparity. Dietary intake of plant lignans was
assessed on the basis of the subjects’ self-reported dietary intake
ranging from 6 months before study entry (Hedelin et al, 2008) to
3 years before breast cancer diagnosis, (dos Santos Silva et al,
2004) and thus, it reflects long-term intake. Enterolactone
concentration that is measured in a single blood sample may be
more indicative of recent dietary habits. There may also be a
significant intra-individual variation in serum response to dietary
* Test for heterogeneity Q= 8.2, df = 3, P= 0.043; I2=63% (95% CI; 0–88%)
0.33 0.5 1 2 3
Combined
Study Combined OR Enterolignan levels ( g day–1)
Lowest category Highest category (95% CI)
McCann (2002) 0.62 (0.47–0.80)
Keinan-Boker (2004) 0.70 (0.46–1.09)
Linseisien (2004) 0.61 (0.39–0.98)
Touillaud (2006, 2007) 0.90 (0.79–1.02)
0.73 (0.57–0.92)*
Cohort studies
Case–control studies
< 530 > 830
 168  3361
 130  2110
< 470.4 > 1163.5
Figure 3 Forest plot of highest vs lowest level of enterolignan exposure and breast cancer risk.
   , test for heterogeneity Q= 23.2, df = 6, P= 0.007; I2= 74% (95% CI; 45 –88%)
 , units for this value are ng ml–1
NP, values not provided
0.33 0.5 1 2 3
Combined
Study
Combined OR Enterolactone levels (nmol l–1)
(95% CI) Lowest category Highest category
0.82 (0.59–1.14) 
Pietinen (2001) 0.38 (0.18–0.77)
Boccardo (2003) 0.27 (0.06–1.26)
Piller (2006) 0.38 (0.17–0.85)
Zeleniuch-Jacquotte (2004)
Olsen (2004)
Kilkkinen (2004)
Hulten (2002) 1.10 (0.70–1.70)
1.30 (0.73–2.31)
0.55 (0.36–0.85)
1.60 (0.70–3.40)
Ward (2008)
Verheus (2007) 1.10 (0.76–1.57)
1.12 (0.70–1.79)
Cohort studies
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Case-control studies
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 0.1  454.6
< 1.3 > 51.1
< 1.48  > 6.24 
NP NP
< 6.19 > 34.80
> 17.1 < 2.4
Figure 4 Forest plot of highest vs lowest enterolactone levels in blood and breast cancer risk.
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levels of enterolactone can be modulated by age, smoking,
frequency of defecation, weight–obesity–body mass index and
regular alcohol intake (Kilkkinen et al, 2001, 2002; Horner et al,
2002; Milder et al, 2007), and these factors could potentially differ
by menopausal status (in particular, age and body mass index). As
bacterial enzymes are involved in lignan metabolism, the use of
antibiotics has also been shown to affect enterolactone serum
concentration (Kilkkinen et al, 2002); antibiotic use was generally
not controlled for in these studies.
It is also possible that the protective effect is caused directly by
the plant lignans or chemicals within the metabolic pathway other
than enterolactone, or even by a synergistic effect between plant
lignans and enterolignans. However, other food constituents found
to be associated with plant lignans may exert the effect. For
example, a-linoleic acid, which is also thought to have anti-cancer
effects (Thompson, 2003; Bougnoux and Chajes, 2003, p. 232), is
found in very high levels in flaxseed, the richest source of plant
lignans (Thompson et al, 1991).
Determining plant lignan intake has various limitations, which
could lead to an over- or under-estimation of food content. Some
food composition databases are incomplete in terms of not
containing values for the more recently discovered plant lignans
(e.g., medioresinol) or for the whole range of foods consumed by
the study population. In addition, there are various analytical
methods for determining food values ; hence, databases compiled
from published values determined by different methodologies may
contain inherent errors. It has also been shown that the amount
of lignans in food can differ according to crop variety, location,
year of harvest and processing (Thompson et al, 1997; Kuijsten
et al, 2005). Dietary measurement error associated with FFQs
(food frequency questionnaires) is also possible. FFQs that were
used varied in length, ranging from 67 to 208 items. Only one
study validated its FFQ specifically for plant lignan assessment
(Torres-Sanchez et al, 2008), although a UK study used the
combination of an FFQ and 24-h recalls to group participants into
quartiles of intake (dos Santos Silva et al, 2004). In addition, the
possibility of residual confounding cannot be ruled out.
Consumption of soy food, rich in isoflavones, has been shown to
reduce breast cancer risk in Asian women but not in Western
women (Wu et al, 2008), suggesting that ethnicity may play a role
in this effect. It is not known whether there are differential
physiologic effects of lignans in people of different races, although
there is some evidence of variation in the urinary excretion of
lignans between white, African American and Latino women
(Horn-Ross et al, 1997). Of the 23 articles used for the meta-
analyses, only 3 American studies provided complete data with
regard to ethnicity (Horn-Ross et al, 2001, 2002; McCann et al,
2004); hence, it was impossible perform sub-analyses for
examining this.
In summary, the meta-analyses presented in this study, indicate
that plant lignans and enterolignans are unlikely to significantly
protect all women against breast cancer development. However,
our results suggest that high plant lignan intake is associated with
a 15% decreased risk in post-menopausal women, which is a small
reduction that could be due to residual confounding. If real, the
reason for the selective effect is not clear. Additional studies of the
effect of lignan exposure on post-menopausal breast cancer risk
are needed to confirm these findings before reassessing the current
dietary guidelines.
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